These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35130287)

  • 1. The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors.
    Takada K; Shimokawa M; Takamori S; Shimamatsu S; Hirai F; Ono Y; Tagawa T; Okamoto T; Hamatake M; Okamoto I; Mori M
    PLoS One; 2022; 17(2):e0263247. PubMed ID: 35130287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival outcomes of patients with nonsmall cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors.
    Baek YH; Kang EJ; Hong S; Park S; Kim JH; Shin JY
    Int J Cancer; 2022 Apr; 150(8):1291-1300. PubMed ID: 34877670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Takamori S; Takada K; Shimokawa M; Jinnnouchi M; Matsubara T; Haratake N; Miura N; Toyozawa R; Yamaguchi M; Takenoyama M; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
    Cancer Immunol Immunother; 2021 Jun; 70(6):1745-1753. PubMed ID: 33389013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting.
    Takada K; Shimokawa M; Takamori S; Shimamatsu S; Hirai F; Tagawa T; Okamoto T; Hamatake M; Tsuchiya-Kawano Y; Otsubo K; Inoue K; Yoneshima Y; Tanaka K; Okamoto I; Nakanishi Y; Mori M
    Int J Cancer; 2021 Jul; 149(2):473-482. PubMed ID: 33720422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Immune Checkpoint Inhibitors in Postoperative Recurrence of Wild-type EGFR Non-Small Cell Lung Cancer.
    Imamura Y; Kato T; Nomata Y; Okado S; Watanabe H; Kawasumi Y; Nakanishi K; Kadomatsu Y; Ueno H; Nakamura S; Mizuno T; Hase T; Tanaka I; Ishii M; Yatsuya H; Chen-Yoshikawa TF
    Anticancer Res; 2024 Aug; 44(8):3451-3461. PubMed ID: 39060057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative Efficacies of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Treatment of Recurrent Non-Small Cell Lung Cancer after Surgery.
    Motono N; Mizoguchi T; Ishikawa M; Iwai S; Iijima Y; Uramoto H
    Oncology; 2024; 102(6):476-483. PubMed ID: 37984347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
    Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C
    Front Immunol; 2023; 14():1070076. PubMed ID: 36776847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between proton pump inhibitor use and systemic anti-tumour therapy on survival outcomes in patients with advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Wei N; Zheng B; Que W; Zhang J; Liu M
    Br J Clin Pharmacol; 2022 Jul; 88(7):3052-3063. PubMed ID: 35165922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of immune checkpoint inhibitors for postoperative recurrence of non-small cell lung cancer.
    Yuasa I; Hamaji M; Ozasa H; Sakamori Y; Yoshida H; Yutaka Y; Menju T; Hirai T; Date H
    Gen Thorac Cardiovasc Surg; 2023 Sep; 71(9):534-541. PubMed ID: 36811789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.
    Ishii H; Azuma K; Kawahara A; Kinoshita T; Matsuo N; Naito Y; Tokito T; Yamada K; Akiba J; Hoshino T
    Thorac Cancer; 2020 Apr; 11(4):950-955. PubMed ID: 32061060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors.
    Giordan Q; Salleron J; Vallance C; Moriana C; Clement-Duchene C
    Front Immunol; 2021; 12():716317. PubMed ID: 34777340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen H; Han KD; He ZJ; Huang YS
    Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating Oral Probiotic Supplements as Complementary Treatment in Advanced Lung Cancer Patients Receiving ICIs: A Prospective Real-World Study.
    Tong L; Wan Y; Shi X; Liu X; Liu Z; Li Y; Zhang Y; Luo D; Zhu J
    Cancer Control; 2024; 31():10732748241253959. PubMed ID: 38736182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Oh MS; Guzner A; Wainwright DA; Mohindra NA; Chae YK; Behdad A; Villaflor VM
    Clin Lung Cancer; 2021 Jan; 22(1):e57-e62. PubMed ID: 32900613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients.
    Peng K; Chen K; Teply BA; Yee GC; Farazi PA; Lyden ER
    Ann Pharmacother; 2022 Apr; 56(4):377-386. PubMed ID: 34282636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study.
    Miura K; Sano Y; Niho S; Kawasumi K; Mochizuki N; Yoh K; Matsumoto S; Zenke Y; Ikeda T; Nosaki K; Kirita K; Udagawa H; Goto K; Kawasaki T; Hanada K
    Thorac Cancer; 2021 Jul; 12(13):1983-1994. PubMed ID: 33990133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer.
    Qin BD; Jiao XD; Zhou XC; Shi B; Wang J; Liu K; Wu Y; Ling Y; Zang YS
    Oncoimmunology; 2021; 10(1):1929727. PubMed ID: 34350061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
    Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T
    Front Immunol; 2021; 12():697298. PubMed ID: 34858389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150.
    Hopkins AM; Kichenadasse G; McKinnon RA; Abuhelwa AY; Logan JM; Badaoui S; Karapetis CS; Rowland A; Sorich MJ
    Br J Cancer; 2022 Jan; 126(1):42-47. PubMed ID: 34711947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.